TreatSMA on Tour – U.K.

It is becoming more apparent than ever that there is a lack of access to physiotherapists for children and adults in the community that specialise in SMA or have knowledge of and training in the condition.

We have been thinking for a while now how best to use the small amount of funds that we have in a way that will widely benefit the community here in the UK. With lots of discussions with Consultant Physiotherapist in Paediatric Neuromuscular disorders Marion Main (MA, MCSP) we have decided to take TreatSMA on Tour starting with Physio workshops done by Marion across the U.K.

Subject to availability your physiotherapists will also be able to join. To do this we need to establish where the need is, what in terms of physio is needed and whether a workshop is wanted or individual sessions or both? We want to make sure the funds raised by the community and friends are used in the best possible way to help the community.

Please select the area most applicable to you and fill out the survey so we can start planning and get the tour on the road ASAP. Thank you.

 

 

 

 

 

 

 

 

 

 

 

 

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more